<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">839</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2021-17-2-14-22</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>MAMMOLOGY. ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>МАММОЛОГИЯ. ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Development of the predictive model for I stage breast cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Разработка прогностической модели для рака молочной железы I стадии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ismagilov</surname><given-names>A. Kh.</given-names></name><name xml:lang="ru"><surname>Исмагилов</surname><given-names>А. Х.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>29 Sibirskiy trakt, Kazan 420029, Russia</p></bio><bio xml:lang="ru"><p>Россия, 420029 Казань, Сибирский тракт, 29</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2347-3535</contrib-id><name-alternatives><name xml:lang="en"><surname>Vanesyan</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Ванесян</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="ES">Spain</country></address><bio xml:lang="en"><p>71 Josep Vicens Foix St., Barcelona 08034, Spain</p></bio><bio xml:lang="ru"><p>Испания, 08034 Барселона, ул. Джозеп Виченц Фуа, 71</p></bio><email>anna_vanesyan@yahoo.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0993-0138</contrib-id><name-alternatives><name xml:lang="en"><surname>Khuzina</surname><given-names>D. R.</given-names></name><name xml:lang="ru"><surname>Хузина</surname><given-names>Д. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>29 Sibirskiy trakt, Kazan 420029, Russia</p></bio><bio xml:lang="ru"><p>Россия, 420029 Казань, Сибирский тракт, 29</p></bio><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kazan State Medical Academy – branch of Federal State Budgetary Educational Institution of Higher Professional Education of Russian Medical Academy of Postgraduate Education of Ministry of Healthcare Russia</institution></aff><aff><institution xml:lang="ru">Казанская государственная медицинская академия – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Clinic «Creu Blanca»</institution></aff><aff><institution xml:lang="ru">Клиника «Креу Бланка»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Tatarstan Regional Clinical Cancer Center</institution></aff><aff><institution xml:lang="ru">ГАУЗ «Республиканский клинический онкологический диспансер» Министерства здравоохранения Республики Татарстан</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-09-20" publication-format="electronic"><day>20</day><month>09</month><year>2021</year></pub-date><volume>17</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><history><date date-type="received" iso-8601-date="2021-09-18"><day>18</day><month>09</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-09-18"><day>18</day><month>09</month><year>2021</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/839">https://ojrs.abvpress.ru/ojrs/article/view/839</self-uri><abstract xml:lang="en"><p><bold>Objective:</bold> development of a predictive model based on binary regression to determine the likelihood of progression of I stage breast cancer.</p><p><bold>Materials and methods. </bold>A retrospective analysis of data of 385 patients with T1N0M0 stage breast cancer was performed. The minimum follow-up period was 120 months and the maximum made 256 months, with an average follow-up of 191 ± 36 months (16 ± 3 years). Using a forward stepwise selection (binary regression), the most important prognostic factors were selected, on the basis of which the predictive model “Risk Assessment Algorithm for Recurrence of Breast Carcinoma” was constructed.</p><p><bold>Results.</bold> During the study period, recurrence of stage I breast cancer was reported in 67 patients, representing 17.4 % of the total cohort. Five prognostic factors were selected by binary regression: grade, histological type, estrogen receptor expression, HER2 / neu overexpression and Ki-67 amplification. Kaplan–Meier analysis and Cox proportional hazards method demonstrated the influence of each of the selected factors on disease-free survival. Comparative analysis with other existing models showed that our prognostic model is inferior to Adjuvant! Online in terms of sensitivity (85 % ver- sus 95 %). However, it is superior in specificity (58 % versus 38 %), PPV (69 % versus 63 %) and AUC (84 % versus 70 %).</p><p><bold>Conclusions.</bold> In I stage breast cancer, factors such as grade, histological type, estrogen receptor expression, HER2 / neu overexpression and Ki-67 amplification are the most significant predictive factors influencing recurrence rates. The algorithm for assessing the risk of recurrence of stage I breast cancer can predict the risk of tumour progression with a sensitivity of 84 % and a specificity of 58 % (p &lt;0.05).</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель работы </bold>– разработка прогностической модели на основании бинарной регрессии с целью определения вероятности прогрессирования рака молочной железы I клинической стадии.</p><p><bold>Материалы и методы.</bold> Выполнен ретроспективный анализ данных 385 больных раком молочной железы стадии T1N0M0. Минимальный период наблюдения за пациентами составил 120 мес, максимальный – 256 мес, средний – 191 ± 36 мес (16 ± 3 года). При помощи прямого пошагового отбора (бинарная регрессия) были отобраны наиболее значимые прогностические факторы, на основании которых построена прогностическая модель «Алгоритм оценки риска рецидивирования карциномы молочной железы».</p><p><bold>Результаты.</bold> За исследуемый период рецидив рака молочной железы I стадии был зарегистрирован у 67 пациенток, что составило 17,4 % от общей когорты. Путем бинарной регрессии были отобраны 5 прогностических факторов: степень дифференцировки опухоли, гистологический тип, экспрессия эстрогеновых рецепторов, гиперэкспрессия HER2 / neu и амплификация Ki-67. Анализ выживаемости по Каплану–Мейеру и пропорциональных рисков Кокса показал влияние каждого из отобранных факторов на безрецидивную выживаемость. Сравнительный анализ с другими существующими моделями продемонстрировал, что разработанная нами прогностическая модель уступает Adjuvant!Online только в плане чувствительности (85 % против 95 %), но при этом превосходит по специфичности (58 % против 38 %), PPV (69 % против 63 %) и AUC (84 % против 70 %).</p><p><bold>Выводы. </bold>При раке молочной железы I стадии наиболее значимыми прогностическими факторами, влияющими на частоту рецидивирования, являются степень дифференцировки опухоли, гистологический тип, экспрессия эстрогеновых рецепторов, гиперэкспрессия HER2 / neu и амплификация Ki-67. Алгоритм оценки риска рецидивирования карциномы молочной железы I клинической стадии способен с чувствительностью 84 % и специфичностью 58 % (p &lt;0,05) прогнозировать риск прогрессирования опухоли.</p></trans-abstract><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>predictive model</kwd><kwd>risk of recurrence</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>прогностическая модель</kwd><kwd>риск рецидивирования рака</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Nielsen T.O., Hsu F.D., Jensen K. et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10(16):5367–74. DOI: 10.1158/1078-0432.CCR-04-0220.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Cheang M.C.U., Voduc D., Bajdik C. et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14(5):1368–76. DOI: 10.1158/1078-0432.CCR-07-1658.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Coates A.S., Winer E.P., Goldhirsch A. et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015;26(8): 1533–46. DOI: 10.1093/annonc/mdv221.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ravdin P.M., Siminoff L.A., Davis G.J. et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19(4):980–91. DOI: 10.1200/JCO.2001.19.4.980.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Killelea B., Gallagher E., Feldman S. et al. The effect of modifiable risk factors on breast cancer aggressiveness among black and white women. Am J Surgery 2019;218(4):689–94. DOI: 10.1016/j.amjsurg.2019.07.012.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>McCartney A., Vignoli A., Biganzoli L. et al. Metabolomics in breast cancer: A decade in review. Cancer Treat Rev 2018;67:88–96. DOI: 10.1016/j.ctrv.2018.04.012.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Cardoso F., Spence D., Mertz S. et al. Global analysis of advanced/metastatic breast cancer: decade report (2005–2015). Breast 2018;39:131–8. DOI: 10.1016/j.breast.2018.03.002.</mixed-citation></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Vanesyan A.S. The investigation of the influence of the breast reconstruction on the quality of life of patients with centralmedial breast cancer. Kreativnaya khirurgiya i onkologiya = Creative Surgery and Oncology 2011;(4):42–7. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Ванесян А.С. Изучение влияния реконструктивно-пластических операций на качество жизни больных раком молочной железы центральной и медиальной локализации. Креативная хирургия и онкология 2011;(4):42–7.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><mixed-citation>Procter M., Robertson C. Imputing missing quality of life data as covariate in survival analysis of the International Breast Cancer Study Group Trials VI and VII. Commun Stat Simul Comput 2019;48(2):580–90. DOI: 10.1080/03610918.2017.1390123.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Gradishar W., Anderson B. Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018;16(3):310–20. DOI: 10.6004/jnccn.2018.0012.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Turner B.M., Gimenez-Sanders M.A., Soukiazian A. et al. Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score &lt;26. Cancer Med 2019;8(9):4176–88.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Xu Y., Kong S., Cheung W.Y. et al. Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data. BMC Cancer 2019;19(1):1–10. DOI: 10.1186/s12885-019-5432-8.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chehade H., Wazir U., Mokbel K. Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature. Am J Surgery 2018;215(1):171–8. DOI: 10.1016/j.amjsurg.2017.05.006.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Phung T. Prognostic models for breast cancer: A systematic review and validation using New Zealand data. BMC Cancer 2019;19(1):230. DOI: 10.1186/s12885-019-5442-6.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kim W., Kim K.S., Lee J.E. et al. Development of novel breast cancer recurrence prediction model using support vector machine. J Breast Cancer 2012;15(2):230–8. DOI: 10.4048/jbc.2012.15.2.230.</mixed-citation></ref></ref-list></back></article>
